GlassScriptPhysician profile
Uma D Gavani
NPI 1710961214
$2,273.08
in general payments reported to CMS, 2019-2025
20 companies · $344 in 2025
The $344 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $349 · 2020: $278 · 2021: $489 · 2022: $521 · 2023: $212 · 2024: $79.87 · 2025: $344.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $538 · Education: $98.34.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $537.53 |
| Education | $98.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $433.98 | 2019-2025 | Nucala |
| Astrazeneca Pharmaceuticals LP | $426.89 | 2019-2024 | Tezspire, Fasenra, Airsupra |
| Regeneron Healthcare Solutions, INC. | $372.73 | 2019-2025 | Dupixent |
| Covis Pharma Gmbh | $232.99 | 2019-2022 | |
| Genzyme Corporation | $162.41 | 2021-2025 | |
| Optinose US, INC. | $116.49 | 2019-2022 | |
| Kaleo, INC. | $97.53 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $90.16 | 2019-2025 | |
| Biocryst US Sales Co., LLC | $55.13 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $43.26 | 2021-2023 | Airduo Digihaler |
| Grifols USA, LLC | $35.56 | 2019-2020 | |
| Aimmune Therapeutics, INC. | $33.04 | 2022 | |
| Amgen INC. | $30.70 | 2022-2023 | Tezspire |
| Csl Behring | $26.18 | 2020 | |
| Pfizer INC. | $24.99 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verona Pharma, INC. | $22.48 | 2025 | Ohtuvayre |
| Ars Pharmaceuticals Operations, INC. | $20.49 | 2025 | Neffy |
| Genentech USA, INC. | $18.10 | 2019 | |
| Alk-Abello, INC | $15.68 | 2019 | |
| Hikma Pharmaceuticals USA | $14.29 | 2024 | Ryaltris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Uma Gavani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.